The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
about
Adapting Drug Approval Pathways for Bacteriophage-Based TherapeuticsPhage therapy of pulmonary infectionsEcology of Anti-Biofilm Agents II: Bacteriophage Exploitation and Biocontrol of Biofilm BacteriaEcology of Anti-Biofilm Agents I: Antibiotics versus BacteriophagesPhage Therapy: a Step Forward in the Treatment of Pseudomonas aeruginosa InfectionsPhage cocktails and the future of phage therapyAntibiotic alternatives: the substitution of antibiotics in animal husbandry?Bacteriophages and phage-derived proteins--application approachesCoevolution with bacteriophages drives genome-wide host evolution and constrains the acquisition of abiotic-beneficial mutations.Taking bacteriophage therapy seriously: a moral argumentPhage treatment of human infections.Experimental phage therapy of burn wound infection: difficult first stepsFinding alternatives to antibiotics.Phages limit the evolution of bacterial antibiotic resistance in experimental microcosms.The susceptibility of Pseudomonas aeruginosa strains from cystic fibrosis patients to bacteriophages.Bacteriophage T4 can produce progeny virions in extremely slowly growing Escherichia coli host: comparison of a mathematical model with the experimental data.Exposure to phages has little impact on the evolution of bacterial antibiotic resistance on drug concentration gradients.Isolation of phages for phage therapy: a comparison of spot tests and efficiency of plating analyses for determination of host range and efficacy.Quality and safety requirements for sustainable phage therapy products.In vitro and in vivo antibacterial activity of environmental bacteriophages against Pseudomonas aeruginosa strains from cystic fibrosis patients.The Janus-Face of Bacteriophages across Human Body Habitats.GP0.4 from bacteriophage T7: in silico characterisation of its structure and interaction with E. coli FtsZExperimental evolution and bacterial resistance: (co)evolutionary costs and trade-offs as opportunities in phage therapy researchEnhancing and initiating phage-based therapies.Rapid identification of international multidrug-resistant Pseudomonas aeruginosa clones by multiple-locus variable number of tandem repeats analysis and investigation of their susceptibility to lytic bacteriophagesLearning from bacteriophages - advantages and limitations of phage and phage-encoded protein applications.Bacteriophage application to control the contaminated water with Shigella.Bacteriophages as Potential Treatment for Urinary Tract InfectionsPaving a regulatory pathway for phage therapy. Europe should muster the resources to financially, technically and legally support the introduction of phage therapy.What are the limitations on the wider therapeutic use of phage?Predicting in vivo efficacy of therapeutic bacteriophages used to treat pulmonary infections.Call for a dedicated European legal framework for bacteriophage therapy.Bacteriophage therapy: potential uses in the control of antibiotic-resistant pathogens.Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine.Bacteriophage based probes for pathogen detection.A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens.Exploring the risks of phage application in the environment.Facing antibiotic resistance: Staphylococcus aureus phages as a medical tool.A bacteriophage journey at the European Medicines Agency.Phage Therapy: Future Inquiries.
P2860
Q26740597-03B3EAD6-71F3-4D1E-A327-56A2A0C25856Q26781119-BF867DEB-B04A-4B31-BB66-E3E9776DBBF5Q26786947-FAADCE1F-83F3-4695-BA65-76BFA27D6ED8Q26786950-08BFA94D-0EBE-4825-BFF3-88254936E411Q26823401-774420C1-2D66-4080-B57E-7ECACC1BF048Q26995797-B417EC90-700C-4CB7-ADEC-ECA1118D1C67Q27027984-C3758445-C686-498E-A2D8-82487BEDA448Q28082731-836728AF-35D7-41D1-9C12-20D5A753972DQ30300777-C9B6072C-7557-4433-8C45-6BF62B99E9E3Q33608714-8F5E12B9-4995-4A68-A200-415B71ABD279Q34254407-C16E111A-A6E0-48ED-96D9-6D8FFB576A13Q34420348-5CC67E4E-3236-4990-B15F-AB410FF04E7BQ34426004-FE3E4B4F-8CD0-4194-A2CD-52416FDD7E85Q34426663-40FD5C4A-D331-4F0E-B7E7-BAC43C8089A3Q34699939-0BD57CFE-3756-4112-B379-8D36F98655D6Q35081370-4EACF14C-AD92-49D4-9E08-B4ACCD2780AEQ35130454-4B5389D6-F00C-4791-9622-5FF6EB61F4E7Q35575223-C461BBBF-4F57-4CDE-9174-92535C5C70FAQ35674419-81358600-4607-4B12-841F-DADE043C1A84Q35780029-6FF046B4-150D-4174-BF77-B6C2787C46F7Q36060279-63D6361C-E9DF-4371-8181-7C3856B77B15Q36076534-882863FE-09B2-49CC-8956-680CDCC5134DQ36105796-2BE69F80-5204-48E7-877C-09CB33562273Q36105880-3D12266D-F4DF-4C93-AA75-05E6F5D50912Q36396094-841D5E5A-DA2D-464A-8222-727BAE6E52CEQ36676044-4C6E3ADD-839D-48B2-8370-F8347ACFBE65Q36682033-FB7BA6B4-CDC4-4AD4-9F7C-2B1746971187Q36784640-12AA3B3A-3B4D-4CE2-B305-9FCC218A045DQ37281307-50A9B8A4-610C-45F5-835F-58ADFD3A5CE3Q37291441-0FF60486-9A2F-4569-A22A-D2F0F16EC91AQ37335751-B4EA0F43-B254-4418-80D4-36ACF73E4481Q37631618-2178B6AF-E7A1-47F8-9B81-DBCABD2DDAACQ37929756-E1EC1F97-AFE8-46B2-95C7-B0D9AB06E1FAQ38004869-57BA9662-4154-427C-9729-E1256951DC69Q38020842-9A446AC4-E18B-498F-805B-F021B9809F55Q38131268-B4668AFC-EEBD-46D3-B7C9-FC31AF716CCEQ38172129-054F1744-8415-4DDB-B150-68F2B9567F29Q38225652-50D15F20-266C-4258-B840-CEB3C05CC1AEQ38560900-94E90D78-803F-42B3-88E1-6AE6CBAAD358Q38911928-B9D771FF-5AD4-4929-B2AF-44FC7C67D6D3
P2860
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
description
im November 2010 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published on 10 November 2010
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в листопаді 2010
@uk
name
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
@en
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
@nl
type
label
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
@en
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
@nl
prefLabel
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
@en
The Phage Therapy Paradigm: Prêt-à-Porter or Sur-mesure?
@nl
P2093
P2860
P50
P1476
The phage therapy paradigm: prêt-à-porter or sur-mesure?
@en
P2093
Andrzej Górski
Daniel De Vos
Elisabeth Kutter
Flavie Pouillot
Geert Laire
Gilbert Verbeken
Guy Van den Mooter
Maia Merabishvili
Martin Zizi
Revaz Adamia
P2860
P304
P356
10.1007/S11095-010-0313-5
P50
P577
2010-11-10T00:00:00Z